Medicenna Therapeutics Corp (MDNA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Medicenna Therapeutics Corp (MDNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014301
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Medicenna Therapeutics Corp (Medicenna) formerly known as A2 Acquisition Corp, is a clinical stage, immuno-oncology company which provides novel first-in-class and interleukin-4 empowered cytokines. The Company’s products under development include MDNA55, MDNA56, MDNA57, fully human interleukin-4 empowered cytokines programs. It develops empowered cytokines to deliver cell killing payloads to the bulk tumor, tumor microenvironment (TME) and cancer stem cells (CSC). Medicenna offers products in the therapeutic areas of CNS cancers in glioblastoma multiforme, brain metastasis, padiatric gliloma, blood cancers, solid tumors and bladder cancers. The company works in partnership with Stanford University, National Institute of Health, Hebrew University of Jerusalem for research and development of cytokines. Medicenna is headquartered in Toronto, Ontario, Canada

Medicenna Therapeutics Corp (MDNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Licensing Agreements 11
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11
Equity Offering 12
Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12
Acquisition 13
A2 Acquisition Acquires Medicenna Therapeutics 13
Medicenna Therapeutics Corp – Key Competitors 14
Medicenna Therapeutics Corp – Key Employees 15
Medicenna Therapeutics Corp – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Financial Announcements 17
Nov 13, 2017: Medicenna Reports Second Quarter Fiscal 2018 Financial Results 17
Aug 09, 2017: Medicenna Reports First Quarter Fiscal 2018 Financial Results 19
Jun 16, 2017: Medicenna Announces March 31, 2017 Year End Results 20
Corporate Communications 22
Oct 18, 2017: Medicenna Announces Trading on the OTCQX Best Market in the United States 22
Sep 21, 2017: Medicenna Appoints Dr. William Li to Board of Directors 23
Jul 17, 2017: Medicenna Bolsters Management Team 24
May 25, 2017: Medicenna Therapeutics Opens the Market 25
Mar 08, 2017: Medicenna shares resume trading under the symbol “MDNA” 26
Jan 18, 2017: Medicenna Further Strengthens Management Team 27
Jan 17, 2017: Medicenna Announces Additions to the Board of Directors 28
Clinical Trials 29
Jun 08, 2017: Medicennas Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology 29
Apr 20, 2017: Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017 30
Apr 13, 2017: Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial 31
Dec 19, 2016: MRI Interventions ClearPoint Neuro Navigation System to be Utilized in Medicenna Therapeutics Phase 2 MDNA55 Clinical Trial for the Treatment of Recurrent Glioblastoma 32
Dec 13, 2016: Medicenna Announces Initiation of Phase 2 Clinical Trial of MDNA55 for the Treatment of Recurrent Glioblastoma 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Medicenna Therapeutics Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11
Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12
A2 Acquisition Acquires Medicenna Therapeutics 13
Medicenna Therapeutics Corp, Key Competitors 14
Medicenna Therapeutics Corp, Key Employees 15
Medicenna Therapeutics Corp, Subsidiaries 16

★海外企業調査レポート[Medicenna Therapeutics Corp (MDNA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lenovo Group Limited:企業の戦略・SWOT・財務分析
    Lenovo Group Limited - Strategy, SWOT and Corporate Finance Report Summary Lenovo Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Siemens Gamesa Renewable Energy SA (SGRE):企業の財務・戦略的SWOT分析
    Siemens Gamesa Renewable Energy SA (SGRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Finning International Inc (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Cosan Ltd:企業の戦略・SWOT・財務情報
    Cosan Ltd - Strategy, SWOT and Corporate Finance Report Summary Cosan Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Alcon Inc (ALC):企業の製品パイプライン分析
    Summary Alcon Inc (Alcon) develops and manufactures devices in the field of ophthalmology. The company’s portfolio encompasses contact lenses and surgical products, including implantables, consumables and surgical equipment. The company's products are indicated for the treatment of various condition …
  • Compania Espanola de Petroleos SAU:企業の戦略・SWOT・財務情報
    Compania Espanola de Petroleos SAU - Strategy, SWOT and Corporate Finance Report Summary Compania Espanola de Petroleos SAU - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Cellectar Biosciences Inc (CLRB):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellectar Biosciences Inc (Cellectar) develops phospholipid drug conjugates (PDCs) for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule radiotherapeutic PDC, being developed for the treatment of relapse or refractory multiple myeloma. Cellectar’s other pr …
  • Proteostasis Therapeutics Inc (PTI):製薬・医療:M&Aディール及び事業提携情報
    Summary Proteostasis Therapeutics Inc (Proteostasis) is a developer of therapies that discovers and develops therapeutics for the treatment of diseases related to defects in protein folding, trafficking and clearance. The company’s portfolio spans drug candidates for cystic fibrosis, neurodegenerati …
  • First Abu Dhabi Bank (FAB):企業の財務・戦略的SWOT分析
    First Abu Dhabi Bank (FAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Avantec Vascular Corp:製品パイプライン分析
    Summary Avantec Vascular Corp (Avantec Vascular), a subsidiary of Goodman Co Ltd is a medical device company that develops cardiovascular interventional and peripheral vascular devices. The company's products comprise balloon catheter, aspiration catheter, device delivery system, micro catheter, gui …
  • Reliance Communications Ltd (RCOM):企業の財務・戦略的SWOT分析
    Reliance Communications Ltd (RCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • ARC Resources Ltd (ARX):企業の財務・戦略的SWOT分析
    ARC Resources Ltd (ARX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • MAN Energy Solutions SE:企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • La Jolla Pharmaceutical Company (LJPC):製薬・医療:M&Aディール及び事業提携情報
    Summary La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company’s major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressu …
  • Kracie Holdings Ltd:企業の戦略的SWOT分析
    Kracie Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Damodar Valley Corp:企業の戦略的SWOT分析
    Damodar Valley Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • InSightec Ltd:製品パイプライン分析
    Summary Insightec Ltd (InSightec), a subsidiary of Elbit Imaging Ltd is a medical device company that develops and markets MR ultrasound based medical devices. The company offers products through divisions such as neurosurgery, oncology and womens’ health. It offers services including commercial dev …
  • Argan Inc (AGX):企業の財務・戦略的SWOT分析
    Argan Inc (AGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Dai-ichi Life Holdings, Inc.:企業のM&A・事業提携・投資動向
    Dai-ichi Life Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dai-ichi Life Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Chimerix Inc (CMRX):企業の財務・戦略的SWOT分析
    Summary Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. Chimer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆